{'fraction_non_alphanumeric': 0.0180623973727422, 'fraction_numerical': 0.006568144499178982, 'mean_word_length': 5.034653465346534, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cord blood quality after vaginal and cesarean deliveries

revision THR, and 37% for revision TKR. Notably, the preoperative mean Hb level for the audit was 12.3 g/dL, which was higher than the pre-EPO mean Hb level of 11.3 g/dL in our study, suggesting that EPO may significantly decrease the proportion of patients requiring transfusion if propagated as Healthcare Trust policy. Transfusion risk and paucity of blood components require imaginative solutions in the modern health care setting. This is particularly relevant in the United Kingdom where vCJD risk is germane. Our results from a small cohort of patients confirm recent findings from the European Epoeitin Alfa Surgery Trial (EEST) that administration of preoperative EPO is associated with a low transfusion rate and few complications among a carefully selected population group. Interestingly, in contrast with the EEST, our study did not administer EPO on the day of surgery for most episodes of care. This and the fact that several of our patients were managed with only two doses of EPO suggests that further studies should be undertaken to establish an optimal EPO regimen, including evaluation of the longer acting erythropoiesisstimulating agents.